Literature DB >> 25656449

BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation.

Fangjie Gao1, Yuanyuan Yang1, Zhengyi Wang2, Xiaoming Gao3, Biao Zheng4.   

Abstract

Germinal center (GC) reaction is a T cell-dependent process in which activated B cells undergo clonal expansion and functional maturation to produce high affinity antibodies and differentiate into memory B cells(1). Here we demonstrate a new role of bromodomain and extraterminal domain (BET) protein BRD4 in GC B cell development. We found that during B cell differentiation stage there was an elevated expression of BRD4 in GC B cells and inhibition of BRD4 by small molecule inhibitors led to the suppression of GC formation and correspondent antibody responses in a Td antigen immunization model. At the molecular level, we found that the effects of BRD4 in primary GC B cell differentiation and B cell lymphoma were mediated through the impaired phosphorylation and translocation of NF-κBp65 and further down-regulation of B-cell lymphoma 6 (Bcl6) expression. Thus this study reveals a novel function of BRD4 in controlling the GC B cell development pathway. Published by Elsevier Inc.

Entities:  

Keywords:  Antibody responses; BRD4; Bcl6; Germinal center B cells

Mesh:

Substances:

Year:  2015        PMID: 25656449     DOI: 10.1016/j.cellimm.2015.01.010

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

Review 1.  Targeting Cancer Cells with BET Bromodomain Inhibitors.

Authors:  Yali Xu; Christopher R Vakoc
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

2.  BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.

Authors:  Michael C Zaiken; Ryan Flynn; Katelyn G Paz; Stephanie Y Rhee; Sujeong Jin; Fathima A Mohamed; Asim Saha; Govindarajan Thangavelu; Paul M C Park; Matthew L Hemming; Peter T Sage; Arlene H Sharpe; Michel DuPage; Jeffrey A Bluestone; Angela Panoskaltsis-Mortari; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Leo Luznik; Ivan Maillard; Geoffrey R Hill; Kelli P A MacDonald; David H Munn; Jonathan S Serody; William J Murphy; Leslie S Kean; Yi Zhang; James E Bradner; Jun Qi; Bruce R Blazar
Journal:  Blood       Date:  2022-05-12       Impact factor: 25.476

3.  JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis.

Authors:  Min Bum Lee; Jun-Ho Lee; Seong Hwi Hong; Jueng Soo You; Seung Taek Nam; Hyun Woo Kim; Young Hwan Park; Dajeong Lee; Keun Young Min; Yeong-Min Park; Young Mi Kim; Hyuk Soon Kim; Wahn Soo Choi
Journal:  BMB Rep       Date:  2017-12       Impact factor: 4.778

Review 4.  Hotspots of MLV integration in the hematopoietic tumor genome.

Authors:  T Tsuruyama; T Hiratsuka; N Yamada
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

5.  Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter-balanced by a strong Th2 bias.

Authors:  Zeinab Dalloul; Marie Best; Pauline Chenuet; Iman Dalloul; Sandrine Le Noir; Dieudonnée Togbé; Mylène Gador; Bernhard Ryffel; Valerie Fj Quesniaux; Yolla El Makhour; François Boyer; Jean-Claude Aldigier; Jeanne Cook-Moreau; Nicolas Fazilleau; Michel Cogné
Journal:  Clin Transl Immunology       Date:  2021-05-30

Review 6.  Epigenetic Codes Programing Class Switch Recombination.

Authors:  Bharat Vaidyanathan; Jayanta Chaudhuri
Journal:  Front Immunol       Date:  2015-09-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.